UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., DR. REDDY'S LABORATORIES, INC. DR. REDDY'S LABORATORIES, LTD., SUN PHARMACEUTICAL INDUSTRIES LTD., SUN PHARMACEUTICAL INDUSTRIES, INC., AND APOTEX INC.
Petitioner

v.
NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00724[1]
Patent 10,335,462

PATENT OWNER'S EXHIBIT LIST

---

[1] IPR2024-00009 (Dr. Reddy's Laboratories); IPR2024-00107 (Sun Pharmaceutical Industries); and IPR2024-00631 (Apotex Inc.) have been joined with this proceeding.

LIST OF EXHIBITS

Exhibit	Description
EX2001	U.S. Patent No. 9,764,003 File History
EX2002	U.S. Patent No. 9,764,003
EX2003	Excerpt of Amended Joint Claim Construction Chart, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-01040-CFC, Dkt. 101 (D. Del. May 23, 2023)
EX2004	Miller, M., et al., "Low Viscosity Highly Concentrated Injectable Nonaqueous Suspensions of Lysozyme Microparticles," Langmuir, Author Manuscript (2011), PMC 2011 (Feb 17)
EX2005	Knight, A., "Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare," Reviews on Recent Clinical Trials, Vol.3, Issue 2, 89-96 (2008)
EX2006	Arrowsmith, J., "Phase II failures: 2008–2010," Nature Reviews, Drug Discovery, Vol. 10 (May 2011)
EX2007	Excerpt of Novo Nordisk's Initial Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-01040-CFC, (D. Del. Dec. 21, 2022)
EX2008	Ozempic®, Prescribing Information (October 2022)
EX2009	Declaration of Sayem Osman
EX2010	Declaration of Julio Rosenstock, M.D.
EX2011	Declaration of George L. Bakris, M.D.
EX2012	Rossing, P., et al., "The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease," Nephrol Dial Transplant, Vol.38, 2041-2051 (2023)
EX2013	Heerspink, H., et al., "Effects of Semaglutide on Albuminuria and Kidney Function in People with Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis from the STEP 1, 2 and 3 Trials," Diabetes Care, Vol.46, Issue 4, 801-810 (2023)
EX2014	Weeda, E., et al., "Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis," Int J Clin Pract., Vol.75 (2021)
EX2015	Shaman, A., et al., "Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients

Exhibit	Description
	With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER," Circulation, Vol.145, 575-585 (2022)
EX2016	Mehdi, S., et al., "Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent," Frontiers in Immunology, Vol. 14 (2023)
EX2017	Novo Nordisk Company Announcement (October 10, 2023)
EX2018	Transcript of December 29, 2023 Deposition of John Bantle, M.D.
EX2019	Transcript of January 5, 2024 Deposition of William J. Jusko, Ph.D.
EX2020	World Trade Organization: Members and Observers, available at https://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm (last visited January 15, 2024)
EX2021	Drug Product: Semaglutide C solution for injection, syringe, Pharmaceutical Development (produced as NN-OZEM-000158851) [UNDER SEAL]
EX2022	April 22, 2009 NN9535-1821 Key Results Meeting Presentation (produced as NN-OZEM-004470861) [UNDER SEAL]
EX2023	April 22, 2009 email from Lise Brondsted to Christine Jensen et al (produced as NN-OZEM-004470860) [UNDER SEAL]
EX2024	May 22, 2009 email from Milan Zdravkovic to Christine Jensen et al (produced as NN-OZEM-004449575) [UNDER SEAL]
EX2025	May 25, 2009 Selection of Doses for Phase 3 presentation (produced as NN-OZEM-004338784) [UNDER SEAL]
EX2026	March 5, 2010 email exchange between Daniel Jonker and Christine Jensen (produced as NN-OZEM-004442953) [UNDER SEAL]
EX2027	March 5, 2010 PK/PD Simulations presentation (produced as NN-OZEM-004442955) [UNDER SEAL]
EX2028	March 17, 2010 Novo Nordisk Diabetes Pipeline Advisory Board Meeting presentation (produced as NN-OZEM-000020275) [UNDER SEAL]
EX2029	May 25, 2010 email from Niklas Ohrner to Christine Jensen (produced as NN-OZEM-004443136) [UNDER SEAL]
EX2030	May 28, 2010 DPComm presentation (produced as NN-OZEM-004443139) [UNDER SEAL]
EX2031	June 9, 2010 End of Phase 2 Meeting Minutes (produced as NN-OZEM-004338845) [UNDER SEAL]
EX2032	April 23, 2012 NN9535-3819 Key Result Meeting presentation (produced as NN-OZEM-004341616) [UNDER SEAL]
EX2033	September 24, 2012 NN9535-3819 Clinical Trial Report (produced as NN-OZEM-000064989) [UNDER SEAL]

Exhibit	Description
EX2034	September 19, 2011 NN9535-3819 Safety Committee Meeting (produced as NN-OZEM-004435305) [UNDER SEAL]
EX2035	September 18, 2011 email from Lisbeth Vesterg Jacobsen to Christine Jensen (produced as NN-OZEM-004435304) [UNDER SEAL]
EX2036	NN9535-3819 CTR Workflow (produced as NN-OZEM-004437994) [UNDER SEAL]
EX2037	--intentionally omitted--
EX2038	March 11, 2010 email from Anne Flint to Nilas Ohrner, copying Christine Jensen (produced as NN-OZEM-004442969) [UNDER SEAL]
EX2039	March 11, 2010 draft Semaglutide Dose selection for phase 3 presentation (produced as NN-OZEM-004442970) [UNDER SEAL]
EX2040	November 26, 2010 draft Clinical Trial Protocol for NN9535-3819 (produced as NN-OZEM-004434630) [UNDER SEAL]
EX2041	November 26, 2010 email from Anne Flint to Christine Jensen et al (produced as NN-OZEM-004434628) [UNDER SEAL]
EX2042	--intentionally omitted--
EX2043	--intentionally omitted--
EX2044	--intentionally omitted--
EX2045	--intentionally omitted--
EX2046	May 20, 2010 DPComm Summary Sheet (produced as NN-OZEM-004338873) [UNDER SEAL]
EX2047	May 28, 2010 DPComm Clipping (produced as NN-OZEM-004338872) [UNDER SEAL]
EX2048	Drug Product Semaglutide B, 1.34 mg/ml, Description and Composition of the Drug Product [UNDER SEAL]
EX2049	Declaration of Devraj Chakravarty
EX2050	Declaration of Christine B. Jensen, Ph.D. [UNDER SEAL AND REDACTED COPIES]
EX2051	Declaration of Anne Flint [UNDER SEAL AND REDACTED COPIES]
EX2052	Declaration of Chloe Jiang
EX2053	Declaration of Smita Agarwal
EX2054	Declaration of Robin S. Goland, M.D.
EX2055	Declaration of Michael J. Blaha, M.D.
EX2056	Declaration of Patrick J. Sinko, Ph.D. [UNDER SEAL AND REDACTED COPIES]
EX2057	Declaration of Jenna DiCicco
EX2058	Declaration of Sayem Osman
EX2059	Declaration of Vanessa Costain

Exhibit	Description
EX2060	Rosenstock, J., et al., "The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes," Diabetes Care, Vol.36, 498-504 (March 2013)
EX2061	Nordqvist, C., "Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended," available at https://www.medicalnewstoday.com/articles/200893#1 (September 13, 2010)
EX2062	Rosenstock, J., et al., "Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes," Diabetes Care, Vol.32, Issue 10, 1880-1886 (October 2009)
EX2063	OPTUMRx, "Tanzeum® (albiglutide) – Drug Discontinuation," available at https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugwithdrawal_tanzeum_2017-0801.pdf (2017)
EX2064	Synapse, "Pegylated GLP-1 analogue (LY2428757) – (Eli Lilly & Co.)," available at https://synapse.patsnap.com/drug/482a547adeba4170ab23efa225fb966d (last updated December 27, 2023)
EX2065	Novo Nordisk, "Annual Report 2010" (February 1, 2011)
EX2066	Kim, K., et al., "Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms," J Clin Pharmacol, Vol.44, 1083-1105 (2004)
EX2067	Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, "Report on the Deliberation Results," available at https://www.pmda.go.jp/files/000153180.pdf (December 3, 2009)
EX2068	Victoza® Prescribing Information (January 2010)
EX2069	Ozempic® Prescribing Information (September 2023)
EX2070	NCT03144271, "Dose Escalation of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects," available at https://clinicaltrials.gov/study/NCT03144271 (last visited December 28, 2023)
EX2071	Claim Construction Order, *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-3038, Dkt. No. 148 (D. Del. July 25, 2023)
EX2072	Ozempic® Prescribing Information (December 2017)

Exhibit	Description
EX2073	Novo Nordisk's Ozempic 0.5 mg solution for injection in pre-filled pen, available at https://www.medicines.org.uk/emc/product/9750/smpc#gref (last visited January 12, 2024)
EX2074	Ozempic® Prescribing Information (Australian Product Information) (December 2020) available at https://www.novonordisk.com.au/content/dam/nncorp/au/en/pdfs/Ozempic%20 Product%20Information%20Nov%202020.pdf (last visited January 12, 2024)
EX2075	Madsbad, S. et al., "Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)," Diabetes Care, Vol.27, Issue 6, 1335-1342 (June 2004)
EX2076	Ozempic® Prescribing Information (March 2022)
EX2077	Mueller, C., "University of South Carolina Upstate, CHEM U109 Chemistry of Living Things," 9.1:Solutions, available at https://chem.libretexts.org/Courses/University_of_South_Carolina__Upstate/ USC_Upstate%3A_CHEM_U109_-_Chemistry_of_Living_Things_(Mueller)/09%3A_Solutions/9.1%3A_Solutions (last visited January 16, 2024)
EX2078	Blüher, M. et al., "Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomized clinical trial," Diabetologia (2023), available at https://link.springer.com/content/pdf/10.1007/s00125-023-06053-9.pdf
EX2079	United States Patent and Trademark Office, Consolidated Trial Practice Guide, Appendix B Default Protective Order (November 2019)
EX2080	Dhruv Khullar, "The Year of Ozempic," New Yorker, December 14, 2023, available at https://www.newyorker.com/culture/2023-in-review/the-year-of-ozempic (last visited January 13, 2024)
EX2081	Dani Blum, "What's Next for Ozempic," New York Times, December 20, 2023
EX2082	M.S. Capehorn *et al.*, "Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)," Diabetes & Metabolism 46 100-109 (2020)

Exhibit	Description
EX2083	V. Aroda *et al.*, "Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicentre, multinational, phase 3a trial," Lancet Diabetes Endocrinol 5:355-66 (2017)
EX2084	R. Pratley *et al.*, "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomized, open-label, phase 3b trial," Lancet Diabetes Endocrinol 6:275-86 (2018)
EX2085	A. Ahmann *et al.*, "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial," Diabetes Care 2018;41:258-266
EX2086	Abdul-Ghani, M., *et al*., Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?, *Diabetes Care*, 40:813-820 (2017).
EX2087	ADA Standards of Medical Care., Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes, *Diabetes Care* 45(Suppl. 1):S144–S175 (2022)
EX2088	American College of Cardiology, "Clinical Topics, Diabetes and Cardiometabolic Disease," https://www.acc.org/Clinical-Topics/Diabetes-and-Cardiometabolic-Disease (last visited Jan. 16, 2024).
EX2089	American Society for Preventive Cardiology, "Cardiometabolic Fellowship," https://www.aspconline.org/professional-development/cardiometabolic-fellowship/ (last visited Jan. 16, 2024).
EX2090	Cosentino, F. *et al*., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, *Eur. Heart J.*, 41:255-323 (2019)
EX2091	Das, S.R., *et al*., ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease, *J. Am. Coll. Cardiol.,* 72: 3200-3223 (2018)
EX2092	Das, S.R., *et al*., Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes, *J. Am. Coll. Cardiol.,* 76: 1117-1145 (2020)
EX2093	Davies, M.J, *et al*., Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes, *Cardiovasc. Diabetol.,* 21:144 (2022)

Exhibit	Description
EX2094	Eckel, R.H. and Blaha, M.J., Cardiometabolic Medicine: A Call for a New Subspecialty Training Track in Internal Medicine, *Am. J. Med.*, 132(7):788-790 (2019).
EX2095	Evans, L.M., *et al.,* A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease, *Endocrinol. Diab. Metab*. 2021;4:e00259 (2021)
EX2096	--intentionally omitted--
EX2097	García-Casares, N., *et al*., Effects of GLP-1 receptor agonists on neurological complications of diabetes, *Rev. Endocr. Metab. Disord.,* 24:655-672 (2023)
EX2098	Jha, K.K., *et al*., Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes, *Curr. Atheroscler. Rep.*, 24:925-937 (2022)
EX2099	Kleindorfer, D.O., *et al*., Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, *Stroke*, 52:e364–e467 (2021)
EX2100	Leiter, L.A., *et al*., Cardiovascular risk reduction with once weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial, *Cardiovasc. Diabetol.,* 18:73 (2019)
EX2101	Marso, S.P., *et al*., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, *N. Engl. J. Med.,* 375:1834-1844 (2016)
EX2102	Marso, S.P., *et al*., Supplementary Appendix to Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, *N. Engl. J. Med.,* 375:1834-1844 (2016)
EX2103	Marx, N., *et al*., GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes, *Circulation,* 146:1882-1894 (2022)
EX2104	Maskery, M.P., *et al.,* Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review, *J. Cereb. Blood Flow Metab.,* 41:14-30 (2020)
EX2105	Nauck, M.A., *et al*., Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors, *Circulation,* 186: 849-870 (2017)
EX2106	Ozempic® FDA Approval Letter (Dec. 15, 2017)
EX2107	Ozempic® FDA Approval Letter for sNDA (March 28, 2022)

Exhibit	Description
EX2108	Reiter-Brennan, C., Comprehensive Care Models for Cardiometabolic Disease, *Curr. Cardiol. Rep.*, 23(3):22 (2021).
EX2109	Sattar, N., *et al*., Novel Diabetes Drugs and the Cardiovascular Specialist, *J. Am. Coll. Cardiol.,* 69: 2646-2656 (2017)
EX2110	Verges, B. and Charbonnel, B., After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? *Diabetes Metab.* 43: 2s3-2s12 (2017)
EX2111	Verma, S., *et al*., Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials, *Diabetes Obes. Metab.,* 22:2487-2492 (2020)
EX2112	Terry, T., *et al.*, Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT, *Curr. Cardiol. Rep.*, 14(1):79-88 (2012).
EX2113	Victoza® FDA Approval Letter (Jan. 25, 2010)
EX2114 to EX2299	--intentionally omitted--
EX2300	Declaration of Christopher A. Vellturo, Ph.D. [UNDER SEAL AND REDACTED COPIES]
EX2301	IQVIA Data [UNDER SEAL]
EX2302	February 27, 2020 Specifications for 2020 Ozempic® People Cover Wrap (produced as NN-OZEM-003176580) [UNDER SEAL]
EX2303	March 3, 2020 Specifications for the "Music Man Digital Exam Room Poster" (produced as NN-OZEM-003176957) [UNDER SEAL]
EX2304	July 30, 2021 internal specifications for the Ozempic® website with savings card details (produced as NN-OZEM-003238568) [UNDER SEAL]
EX2305	September 13, 2021 internal specifications for the Ozempic® website with savings card details (produced as NN-OZEM-003242796) [UNDER SEAL]
EX2306	January 30, 2018 Brand Strategy presentation (produced as NN-OZEM-003732069) [UNDER SEAL]
EX2307	January 12, 2018 Ozempic ® Brand Presentation (produced as NN-OZEM-003732120) [UNDER SEAL]
EX2308	July 6, 2018 Product Development Plan, Ozempic® NN9535 (produced as NN-OZEM-003735283) [UNDER SEAL]

Exhibit	Description
EX2309	September 18, 2018 Semaglutide NNI Evidence Generation Plan – 2018-2021/25 presentation (produced as NN-OZEM-003793796) [UNDER SEAL]
EX2310	September 22, 2018 SC Semaglutide QW, US RWE Plan presentation (produced as NN-OZEM-003971783) [UNDER SEAL]
EX2311	June 13, 2017 Market Access – Track 6 presentation (produced as NN-OZEM-004055726) [UNDER SEAL]
EX2312	September 5, 2018 Novo Nordisk/Non-Insulin Market Weekly Performance Report spreadsheet (produced as NN-OZEM-004063922) [UNDER SEAL]
EX2313	November 5, 2019 Market Overview/GLP-1 Strategy presentation (produced as NN-OZEM-004300946) [UNDER SEAL]
EX2314	May 16, 2017 Semaglutide Ad Board Market Overview presentation (produced as NN-OZEM-004656390) [UNDER SEAL]
EX2315	November 5, 2019 Ozempic® US Launch Tracker presentation (produced as NN-OZEM-004677154) [UNDER SEAL]
EX2316	May 6, 202 Integrated Insights Ecosystem, Wave 1 Quarterly Insights Report presentation (produced as NN-OZEM-004679316) [UNDER SEAL]
EX2317	June 2, 2021 Integrated Insights Ecosystem, 2021 Q1 Quarterly Insights Report presentation (produced as NN-OZEM-004680250) [UNDER SEAL]
EX2318	March 28, 2018 GfK RepInsight® spreadsheet (produced as NN-OZEM-004681464) [UNDER SEAL]
EX2319	--intentionally omitted--
EX2320	September 12, 2018 GLP-1 ATU 3Q18, West Area Analysis presentation (produced as NN-OZEM-004684107) [UNDER SEAL]
EX2321	September 10, 2018 GLP-1ATU 3Q18 presentation (produced as NN-OZEM-004684467) [UNDER SEAL]
EX2322	February 17, 2021 Integrated Insights Ecosystem, Wave 4 Quarterly Insights Report presentation (produced as NN-OZEM-004687270) [UNDER SEAL]
EX2323	February 26, 2019 Ozempic® US Launch Tracker presentation (produced as NN-OZEM-004688496) [UNDER SEAL]
EX2324	May 2017 Brand Strategy 2018 GLP-1 Franchise presentation (produced as NN-OZEM-004690786) [UNDER SEAL]

Exhibit	Description
EX2325	February 23, 2022 Quarterly Insights Report – Q4' 2021, Diabetes Integrated Insights Ecosystem presentation (produced as NN-OZEM-004691302) [UNDER SEAL]
EX2326	November 16, 2021 Quarterly Insights Report – Q3' 2021, Diabetes Integrated Insights Ecosystem presentation (produced as NN-OZEM-004691816) [UNDER SEAL]
EX2327	February 17, 2021 Integrated Insights Ecosystem, Wave 4 Quarterly Insights Report presentation (produced as NN-OZEM-004701779) [UNDER SEAL]
EX2328	August 8, 2021 specifications for detailing material (produced as NN-OZEM-004717717) [UNDER SEAL]
EX2329	January 4, 2021 CV Region New Year Kick-Off Meeting presentation (produced as NN-OZEM-004723449) [UNDER SEAL]
EX2330	November 11, 2020 Integrated Insights Ecosystem, Wave 3 Quarterly Report presentation (produced as NN-OZEM-004723593) [UNDER SEAL]
EX2331	May 6, 2020 Integrated Insights Ecosystem, Wave 1 Quarterly Report presentation (produced as NN-OZEM-004724606) [UNDER SEAL]
EX2332	May 2017 GLP-1 Franchise Patient Segmentation, Results & Recommendations presentation (produced as NN-OZEM-004731509) [UNDER SEAL]
EX2333	August 11, 2020 Integrated Insights Ecosystem, Wave 2 Quarterly Report presentation (produced as NN-OZEM-004741982) [UNDER SEAL]
EX2334	January 17, 2018 Pre-POA opening presentation (produced as NN-OZEM-004751127) [UNDER SEAL]
EX2335 to EX2350	--intentionally omitted--
EX2351	National Institute of Diabetes and Digestive Kidney Diseases, "What is Diabetes," https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes, last reviewed April 2023.
EX2352	Mayo Clinic, "Diabetes – Symptoms & causes," https://www.mayoclinic.org/diseases-conditions/diabetes/symptoms-causes/syc-20371444, last updated Sept. 15, 2023.
EX2353	Mayo Clinic, "Hyperglycemia in diabetes – Symptoms & causes," https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631, last updated Aug. 20, 2022.

Exhibit	Description
EX2354	Centers for Disease Control and Prevention, "Gestational Diabetes," https://www.cdc.gov/diabetes/basics/gestational.html, last reviewed Dec. 30, 2022.
EX2355	National Institute of Diabetes and Digestive Kidney Diseases, "Dictionary Definition: insulin," https://www.niddk.nih.gov/Dictionary/I/insulin.
EX2356	Centers for Disease Control and Prevention, National Diabetes Statistics Report 2020: Estimates of Diabetes and Its Burden in the United States (2020).
EX2357	National Institute of Diabetes and Digestive Kidney Diseases, "Type 2 Diabetes," https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/type-2-diabetes, last reviewed May 2017.
EX2358	Mayo Clinic, "Type 2 diabetes – Diagnosis & Treatment," https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199, last updated March 14, 2023.
EX2359	Moses, R.G., Combination Therapy for Patients with Type 2 Diabetes: Repaglinide in Combination with Metformin, Overview of Oral Antidiabetic Medications, https://www.medscape.com/viewarticle/722513_3
EX2360	Quianzon, C. C.L. and Cheick, I.E., History of current non-insulin medications for diabetes mellitus, *J. Community Hosp. Intern. Med. Perspect.* 2012 Oct. 15; 2(3). Doi: 10.3402/jchimp.v2i3.19081.
EX2361	National Institute of Diabetes and Digestive and Kidney Diseases, "Low Blood Glucose (Hypoglycemia)," https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia, last reviewed July 2021.
EX2362	U.S. Food & Drug Administration, Drugs@FDA, Diabeta®
EX2363	U.S. Food & Drug Administration, Drugs@FDA, Micronase®
EX2364	U.S. Food & Drug Administration, Drugs@FDA, Glucotrol®
EX2365	U.S. Food & Drug Administration, Drugs@FDA, Amaryl®
EX2366	Cleveland Clinic, "Biguanides," https://my.clevelandclinic.org/health/treatments/25004-biguanides, last reviewed May 22, 2023.
EX2367	Sirtori, C.R. and Pasik, C., Re-evaluation of a biguanide, metformin: mechanism of action and tolerability, *Pharmacol. Res.* 1994 Oct-Nov; 30(3):187-228.
EX2368	Tomkin, G.H., Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, *World J. Diabetes*, 2014 Oct. 15; 5(5):636-650.

Exhibit	Description
EX2369	U.S. Food & Drug Administration, Drugs@FDA, Glucophage®
EX2370	White, Jr., J.R., A Brief History of the Development of Diabetes Medications, *Diabetes Spectr.* 2014;27(2):82-86.
EX2371	U.S. Food & Drug Administration, Drugs@FDA, Prandin®
EX2372	Eggleton, J.S. and Jialal, I., Thiazolidinediones, StatPearls [Internet], available at https://www.ncbi.nlm.nih.gov/books/NBK551656/, last updated Feb. 20, 2023.
EX2373	Cleveland Clinic, "GLP-1 Agonists," https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists, last reviewed July 3, 2023.
EX2374	Tran, K.L., et al., Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes, *Am. Health Drug Benefits* 2017 Jun; 10(4):178-188.
EX2375	U.S. Food & Drug Administration, Approval Letter for Januvia® (Oct. 16, 2006)
EX2376	Kalra, S., Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology, *Diabetes Ther.*, 2014 Dec.; 5(2):355-366.
EX2377	Janssen Pharmaceuticals, Inc., "U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes," https://www.prnewswire.com/news-releases/us-fda-approves-invokana-canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-200638361.html (Mar. 29, 2013)
EX2378	American Diabetes Association, "Life with Diabetes: Get the Right Care for You," http://www.diabetes.org/living-with-diabetes/treatment-and-care.
EX2379	Novo Nordisk, "Managing your diabetes," https://www.mynovoinsulin.com/diabetes-education/managing-diabetes.html, last updated Dec. 2022.
EX2380	Mayo Clinic, "A1C test," https://www.mayoclinic.org/tests-procedures/a1c-test/about/pac-20384643, last updated Dec. 1, 2022.
EX2381	Valentine, V., Goldman, J. and Shubrook, J.H., Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes, *Diabetes Ther.*, 2017 July; 8:739-752.
EX2382	Boyes, K.S., et al., Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States, *Diabetes Ther.*, 2023 Nov., https://doi.org/10.1007/s13300-023-01499-x.

Exhibit	Description
EX2383	Bishop, S., "Losing Weight Can Have Big Impact on Those With Diabetes," https://newsnetwork.mayoclinic.org/discussion/losing-weight-can-have-big-impact-on-those-with-diabetes (Dec. 14, 2012).
EX2384	Clamp, L.D., et al., Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history, *Nutrition & Diabetes*, 2017; 7:e282
EX2385	Wilding, J.P.H., The importance of weight management in type 2 diabetes mellitus, *Int. J. Clin. Pract.*, 2014 Jun; 68(6):682-691
EX2386	National Institute for Health and Care Research, "Losing weight following type 2 diabetes diagnosis boosts chance of remission," https://evidence.nihr.ac.uk/not-articletype/losing-weight-following-type-2-diabetes-diagnosis-boosts-chance-of-remission (Nov. 21, 2019)
EX2387	American Heart Association, "Cardiovascular Disease and Diabetes," https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks/cardiovascular-disease--diabetes, last reviewed May 4, 2021.
EX2388	Cramer, J.A., Medication compliance and persistence: terminology and definitions, *Value Health* 2008 Jan-Feb; 11(1):44-47.
EX2389	Ho, P.M., Bryson, C.L., and Rumsfeld, J.S., Medication Adherence, *Circulation*, 2009; 119(23):3028-3035.
EX2390	Usherwood, T., Encouraging adherence to long-term medication, *Aust. Prescr.*, 2017 Aug.; 40(4):147-150.
EX2391	Brown, M.T. and Bussell, J.K., Medication Adherence: WHO Cares?, *Mayo Clin. Proc.*, 2011 Apr.; 86(4): 304-314.
EX2392	Baryakova, T.H., et al., Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems, *Nature Reviews Drug Discovery*, 2023; 22:387-409.
EX2393	DiBonaventura, M.d., et al., Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication, *Patient Prefer. Adherence*, 2010; 4:397-406.
EX2394	Mansfield, C., et al., Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey, *Diabetes Ther.*, 2017 Dec.; 8(6):1365-1378.
EX2395	Byetta® Prescribing Information (rev. Feb. 2015)
EX2396	U.S. Food & Drug Administration, Drugs@FDA, Byetta®
EX2397	U.S. Food & Drug Administration, FDA List of Authorized Generics, https://www.fda.gov/media/77725/download, last updated Jan. 4, 2024
EX2398	Januvia® Prescribing Information (rev. Feb. 2018)
EX2399	U.S. Food & Drug Administration, Drugs@FDA, Januvia®

Exhibit	Description
EX2400	Janumet® Prescribing Information (rev. Feb. 2018)
EX2401	U.S. Food & Drug Administration, Drugs@FDA, Janumet®
EX2402	U.S. Food & Drug Administration, Drugs@FDA, Janumet® XR
EX2403	Onglyza® Prescribing Information (rev. Feb. 2017)
EX2404	U.S. Food & Drug Administration, Drugs@FDA, Onglyza®
EX2405	U.S. Food & Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 205981
EX2406	Aurobindo, "Aurobindo Received FDA Approval for Saxagliptin Tablets, 2.5mg and 5mg," https://www.aurobindousa.com/news/product-news/aurobindo-receives-fda-approval-for-saxagliptin-tablets-2-5mg-and-5mg/ (July 31, 2023).
EX2407	Victoza® Prescribing Information (rev. Nov. 2020)
EX2408	U.S. Food & Drug Administration, Drugs@FDA, Victoza®
EX2409	Victoza® Prescribing Information (rev. Aug. 2017)
EX2410	Novo Nordisk, "Dosing and administering Victoza®," https://www.novomedlink.com/diabetes/products/treatments/victoza/dosing-administration.html.
EX2411	Kombiglyze® XR Prescribing Information (rev. Feb. 2017)
EX2412	U.S. Food & Drug Administration, Drugs@FDA, Kombiglyze® XR
EX2413	U.S. Food & Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 206081
EX2414	Tradjenta® Prescribing Information (rev. Aug. 2017)
EX2415	U.S. Food & Drug Administration, Drugs@FDA, Tradjenta®
EX2416	U.S. Food & Drug Administration, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 208335
EX2417	AstraZeneca, "AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes alliance through Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals," https://www.astrazeneca.com/media-centre/press-releases/2012/AstraZeneca-and-Bristol-Myers-Squibb-complete-expansion-of-diabetes-alliance-through-Bristol-Myers-Squibbs-acquisition-of-Amylin-Pharmaceuticals-09082012.html (Aug. 9, 2012)
EX2418	U.S. Food & Drug Administration, Drugs@FDA, Bydureon®
EX2419	--intentionally omitted--
EX2420	Bydureon® BCISE™ Prescribing Information (rev. Oct. 2017)
EX2421	U.S. Food & Drug Administration, Drugs@FDA, Bydureon® BCISE™
EX2422	Jentadueto® Prescribing Information (rev. Aug. 2017)
EX2423	U.S. Food & Drug Administration, Drugs@FDA, Jentadueto®
EX2424	U.S. Food & Drug Administration, Drugs@FDA, Jentadueto® XR

Exhibit	Description
EX2425	Jentadueto® XR Prescribing Information (rev. Dec. 2016)
EX2426	Nesina® Prescribing Information (rev. Dec. 2016)
EX2427	U.S. Food & Drug Administration, Drugs@FDA, Nesina®
EX2428	Kazano® Prescribing Information (rev. Feb. 2017)
EX2429	U.S. Food & Drug Administration, Drugs@FDA, Kazano®
EX2430	Oseni® Prescribing Information (rev. Dec. 2017)
EX2431	U.S. Food & Drug Administration, Drugs@FDA, Oseni®
EX2432	Invokana® Prescribing Information (rev. July 2017)
EX2433	U.S. Food & Drug Administration, Drugs@FDA, Invokana®
EX2434	Farxiga® Prescribing Information (rev. Oct. 2017)
EX2435	U.S. Food & Drug Administration, Drugs@FDA, Farxiga®
EX2436	Tanzeum® Prescribing Information (rev. Dec. 2017)
EX2437	U.S. Food & Drug Administration, Drugs@FDA, Tanzeum®
EX2438	Hoerman, J., "Tanzeum (albiglutide) Discontinued After FDA Warns of Risk of Anaphylaxis Reaction," https://trulaw.com/fda/tanzeum-albiglutide-anaphylaxis-reaction (Nov. 21, 2017).
EX2439	Jardiance® Prescribing Information (rev. Dec. 2017)
EX2440	U.S. Food & Drug Administration, Drugs@FDA, Jardiance®
EX2441	Jardiance® Prescribing Information (rev. Dec. 2016)
EX2442	Invokamet® Prescribing Information (rev. Aug. 2017)
EX2443	U.S. Food & Drug Administration, Drugs@FDA, Invokamet®
EX2444	U.S. Food & Drug Administration, Drugs@FDA, Invokamet® XR
EX2445	Trulicity® Prescribing Information (rev. Aug. 2017)
EX2446	Trulicity® Prescribing Information (rev. June 2018)
EX2447	U.S. Food & Drug Administration, Drugs@FDA, Trulicity®
EX2448	Xigduo® XR Prescribing Information (rev. July 2017)
EX2449	U.S. Food & Drug Administration, Drugs@FDA, Xigduo® XR
EX2450	Glyxambi® Prescribing Information (rev. Dec. 2017)
EX2451	U.S. Food & Drug Administration, Drugs@FDA, Glyxambi®
EX2452	Synjardy® Prescribing Information (rev. Dec. 2017)
EX2453	U.S. Food & Drug Administration, Drugs@FDA, Synjardy®
EX2454	U.S. Food & Drug Administration, Drugs@FDA, Synjardy® XR
EX2455	Adlyxin® Prescribing Information (rev. July 2016)
EX2456	U.S. Food & Drug Administration, Drugs@FDA, Adlyxin®
EX2457	Soliqua® 100/33 Prescribing Information (rev. Aug. 2017)
EX2458	U.S. Food & Drug Administration, Drugs@FDA, Soliqua® 100/33
EX2459	Xultophy® 100/3.6 Prescribing Information (rev. Nov. 2016)
EX2460	U.S. Food & Drug Administration, Drugs@FDA, Xultophy® 100/3.6

Exhibit	Description
EX2461	Qtern® Prescribing Information (rev. Feb. 2017)
EX2462	U.S. Food & Drug Administration, Drugs@FDA, Qtern®
EX2463	U.S. Food & Drug Administration, Drugs@FDA, Ozempic®
EX2464	Steglatro® Prescribing Information (rev. Dec. 2017)
EX2465	U.S. Food & Drug Administration, Drugs@FDA, Steglatro®
EX2466	Steglujan® Prescribing Information (rev. Feb. 2018)
EX2467	U.S. Food & Drug Administration, Drugs@FDA, Steglujan®
EX2468	Stegluromet® Prescribing Information (rev. Dec. 2017)
EX2469	U.S. Food & Drug Administration, Drugs@FDA, Stegluromet®
EX2470	Rybelsus® Prescribing Information (rev. Jan. 2020)
EX2471	U.S. Food & Drug Administration, Drugs@FDA, Rybelsus®
EX2472	Trijardy® XR Prescribing Information (rev. Jan. 2020)
EX2473	U.S. Food & Drug Administration, Drugs@FDA, Trijardy® XR
EX2474	U.S. Food & Drug Administration, Drugs@FDA, Mounjaro®
EX2475	Mounjaro® Prescribing Information (rev. July 2023)
EX2476	Brenzavvy® Prescribing Information (rev. Jan. 2023)
EX2477	U.S. Food & Drug Administration, Drugs@FDA, Brenzavvy®
EX2478	Chen, J., "Blockbuster Drug: What it is, How it works," *Investopedia*, https://www.investopedia.com/terms/b/blockbuster-drug.asp, last updated Sept. 6, 2022.
EX2479	Nordrum, A., "11 Blockbuster 'Drugs to Watch' in 2015," *Int'l Bus. Times*, http://www.ibtimes.com/11-blockbuster-drugs-watch-2015-1857100 (Mar. 24, 2015)
EX2480	IQVIA, "About us," https://www.iqvia.com/about-us
EX2481	"FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease," https://www.drugs.com/newdrugs/fda-approves-ozempic-semaglutide-cardiovascular-risk-reduction-adults-type-2-diabetes-known-heart-5143.html (Jan. 16, 2020)
EX2482	Novo Nordisk, "Possible Side Effects of Ozempic® (semaglutide) Injection," https://www.ozempic.com/how-to-take/side-effects.html
EX2483	IQVIA, "Available IQVIA Data," https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data
EX2484	IMS Institute for Healthcare Informatics, "Price Declines after Branded Medicines Lose Exclusivity in the U.S." (Jan. 2016), available at https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf
EX2485	U.S. Food & Drug Administration, Drugs@FDA, Actos®

Exhibit	Description
EX2486	U.S. Food & Drug Administration, Drugs@FDA, Avandia®
EX2487	U.S. Patent No. 8,129,343
EX2488	U.S. Patent No. 8,536,122
EX2489	--intentionally omitted--
EX2490	--intentionally omitted--
EX2491	--intentionally omitted--
EX2492	--intentionally omitted--
EX2493	--intentionally omitted--
EX2494	Novo Nordisk, Financial report for the period 1 January 2018 to 31 March 2018 (May 2, 2018)
EX2495	Novo Nordisk, Financial report for the period 1 January 2018 to 30 June 2018 (Aug. 8, 2018)
EX2496	Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 (Nov. 1, 2018)
EX2497	Novo Nordisk, Financial report for the period 1 January 2018 to 31 December 2018 (Feb. 1, 2019)
EX2498	Novo Nordisk, Financial report for the period 1 January 2019 to 31 March 2019 (May 3, 2019)
EX2499	Novo Nordisk, Financial report for the period 1 January 2019 to 30 June 2019 (Aug. 9, 2019)
EX2500	Novo Nordisk, Financial report for the period 1 January 2019 to 30 September 2019 (Nov. 1, 2019)
EX2501	Novo Nordisk, Financial report for the period 1 January 2019 to 31 December 2019 (Feb. 5, 2020)
EX2502	Novo Nordisk, Financial report for the period 1 January 2020 to 31 March 2020 (May 6, 2020)
EX2503	Novo Nordisk, Financial report for the period 1 January 2020 to 30 June 2020 (Aug. 6, 2020)
EX2504	Novo Nordisk, Financial report for the period 1 January 2020 to 30 September 2020 (Oct. 30, 2020)
EX2505	Novo Nordisk, Financial report for the period 1 January 2020 to 31 December 2020 (Feb. 3, 2021)
EX2506	Novo Nordisk, Financial report for the period 1 January 2021 to 31 March 2021 (May 5, 2021)
EX2507	Novo Nordisk, Financial report for the period 1 January 2021 to 30 June 2021 (Aug. 4, 2021)
EX2508	Novo Nordisk, Financial report for the period 1 January 2021 to 30 September 2021 (Nov. 3, 2021)

Exhibit	Description
EX2509	Novo Nordisk, Financial report for the period 1 January 2021 to 31 December 2021 (Feb. 2, 2022)
EX2510	Novo Nordisk, Financial report for the period 1 January 2022 to 31 March 2022 (Apr. 29, 2022)
EX2511	Novo Nordisk, Financial report for the period 1 January 2022 to 30 June 2022 (Aug. 3, 2022)
EX2512	Novo Nordisk, Financial report for the period 1 January 2022 to 30 September 2022 (Nov. 2, 2022)
EX2513	Novo Nordisk, Financial report for the period 1 January 2022 to 31 December 2022 (Feb. 1, 2023)
EX2514	Novo Nordisk, Financial report for the period 1 January 2023 to 31 March 2023 (May 4, 2023)
EX2515	Novo Nordisk, Financial report for the period 1 January 2023 to 30 June 2023 (Aug. 10, 2023)
EX2516	Novo Nordisk, Financial report for the period 1 January 2023 to 30 September 2023 (Nov. 2, 2023)
EX2517	Merck Provides Update on Combination Medicine JUVISYNC™ (sitagliptin and simvastatin) Tablets, https://www.merck.com/news/merck-provides-update-on-combination-medicine-juvisync-sitagliptin-and-simvastatin-tablets/ (Sept. 26, 2013)
EX2518	Han, S.H., et al., Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis, *Aesthetic Surgery J.*, 2024 Jan.; 44(1):60-67
EX2519	Gorgojo-Martínez, J.J., et al., Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus, *J. Clin. Med.*, 2023 Jan.; 12(1):145
EX2520	NYU Langone Health, "Medication for Type 2 Diabetes," https://nyulangone.org/conditions/type-2-diabetes/treatments/medication-for-type-2-diabetes
EX2521	Bibeau, W.S., et al., Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes, *J. Manag. Care Spec. Pharm.*, 2016 Nov.; 22(11):1338-1347
EX2522	Novo Nordisk, "Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg: WAC Price," https://www.novopricing.com/ozempic.html, last updated Oct. 2023.
EX2523	Eli Lilly & Co., SEC Form 10-K for the Year Ended December 31, 2022 (Feb. 22, 2023)

Exhibit	Description
EX2524	Eli Lilly & Co., 2019 Financial Report
EX2525	Eli Lilly & Co., 2018 Financial Report
EX2526	Eli Lilly & Co., SEC Form 10-Q for the Quarter Ended September 30, 2023 (Nov. 2, 2023)
EX2527	Eli Lilly & Co., SEC Form 10-Q for the Quarter Ended June 30, 2023 (Aug. 8, 2023)
EX2528	Eli Lilly & Co., SEC Form 10-Q for the Quarter Ended March 31, 2023 (Apr. 27, 2023)
EX2529	Eli Lilly & Co., Income Statements for Year Ending 2019 to 2022, https://investor.lilly.com/financial-information/fundamentals/income-statement, last visited Jan. 14, 2024.
EX2530	Janumet® XR Prescribing Information (rev. Feb. 2012)
EX2531	Invokamet® and Invokamet® XR Prescribing Information (rev. July 2023)
EX2532	Synjardy® and Synjardy® XR Prescribing Information (rev. Oct. 2023)
EX2533	Novo Nordisk Partnering (Oct. 2008)
EX2534	Declaration of Philip S. May
EX2535	Declaration of Jenny C. Wu
EX2536	Partial Transcript of July 22, 2024 Teleconference
EX2537	Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (D. Del. Mar. 19, 2024)
EX2538	Opening Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335, 462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (D. Del. Mar. 19, 2024)
EX2539	Notice of Service, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-md-03038-CFC (Dkt. 330)
EX2540	Email Exchange Between Counsel for Petitioner and Counsel for Patent Owner Regarding Request for a *Sotera* Stipulation
EX2541	Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s Stipulation Concerning Invalidity Grounds, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 334)
EX2542	Sun Pharmaceutical Industries Ltd.'s and Sun Pharmaceutical Industries Inc.'s Stipulation of Invalidity Contentions, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 333)
EX2543	Email Exchange Between Counsel for Sun Pharmaceutical Industries, Ltd. and Counsel for Patent Owner Regarding Request to File Stipulation, *Sun Pharmaceutical Industries, Ltd. v. Novo Nordisk A/S*, IPR2024-00107, EX2031

Exhibit	Description
EX2544	Defendants' Notice of Deposition of Stephanie Dechiaro, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 265)
EX2545	Petitioners' Motion for Joinder Under 35 U.S.C. § 315(c) and 37 C.F.R. §§ 42.22 and 42.122(b), *Dr. Reddy's Laboratories Inc. v. Novo Nordisk A/S*, IPR2024-00009, Pap.3 (Oct. 20, 2023)
EX2546	Petitioner's Motion for Joinder Under 35 U.S.C. § 315(c) and 37 C.F.R. §§ 42.22 and 42.122(b), *Sun Pharmaceutical Industries Ltd. v. Novo Nordisk A/S*, IPR2024-00107, Pap.2 (Nov. 2, 2023)
EX2547	Email Notice of Electronic Filing Corresponding to *In re Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 314)
EX2548	Email Notice of Electronic Filing Corresponding to *In re Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 333)
EX2549	Email Notice of Electronic Filing Corresponding to *In re Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 334)
EX2550	Sun Pharmaceutical Industries Ltd.'s and Sun Pharmaceutical Industries Inc.'s Stipulation of Invalidity Contentions, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (Dkt. 314)
EX2551	Opening Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (D. Del. Mar. 19, 2024)
EX2552	Transcript of July 11, 2024 Deposition of John Bantle, M.D.
EX2553	Transcript of July 12, 2024 Deposition of William J. Jusko, Ph.D.
EX2554	Transcript of July 16, 2024 Deposition of Steven Coca, M.D.
EX2555	Transcript of July 19, 2024 Deposition of DeForest McDuff [UNDER SEAL AND REDACTED COPIES]
EX2556	Transcript of July 26, 2024 Deposition of Allen Spiegel, M.D.
EX2557	Transcript of July 9, 2024 Deposition of Arthur Z. Schwartzbard, M.D.
EX2558	February 26, 2010 DPComm Brief Summary Sheet (produced as NN-OZEM-004442611) (Marked As Exhibit 9 at C. Jensen Deposition) [UNDER SEAL]
EX2559 – EX2600	--intentionally omitted--
EX2601	T. Wilcox, A. Schwartzbard, *et. al*, *Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists*, JACC Focus Seminar, JACC Vol. 75 (2020) (Marked As Exhibit 2601 at Arthur Z. Schwartzbard Deposition)

Exhibit	Description
EX2602	J. Newman, A. Schwartzbard, *et. al*, *The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction*, JACC State-of-the-Art Review, JACC Vol. 72 (2018) (Marked As Exhibit 2602 at Arthur Z. Schwartzbard Deposition)
EX2603	S. Coca *et. al*, *Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus*, Arch. Intern. Med. Vol. 172 (2012) (Marked As Exhibit 09/2603 at Steven Coca Deposition)
EX2604	V. Perkovic et. al., *Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes*, N. Engl. J. Med. (May 24, 2024) (Marked As Exhibit 11/2604 at Steven Coca Deposition)
EX2605 – EX2609	--intentionally omitted--
EX2610	Trackdrugs.com Homepage (Marked As Exhibit 2610 at DeForest McDuff Deposition)
EX2611 – EX2649	--intentionally omitted--
EX2650	Excerpt of Reply Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (D. Del. July 16, 2024)
EX2651	Excerpt of Reply Expert Report of Dr. Paul Dalby Regarding Invalidity of U.S. Patent No. 10,335, 462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (D. Del. July 16, 2024)
EX2652	Excerpt of Reply Expert Report of William J. Jusko, Ph.D. Regarding Invalidity of U.S. Patent No. 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-03038-CFC (D. Del. July 16, 2024)
EX2653	July 8, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding "IPR2023-00724 – Service of draft proposed motion for sanctions"
EX2654	July 10, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding "IPR2023-00724 – Service of draft proposed motion for sanctions"
EX2655	July 2, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding "IPR2023-00724 – Service of draft proposed motion for sanctions"

Exhibit	Description
EX2656	July 12, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding "IPR2023-00724 – Service of draft proposed motion for sanctions"
EX2657	Mylan Pharmaceuticals Inc. and Novo Nordisk Settlement Agreement [UNDER SEAL AS CONTAINING BUSINESS CONFIDENTIAL INFORMATION]
EX2658	Mylan Pharmaceuticals Inc. and Novo Nordisk Settlement Agreement [UNDER SEAL AS CONTAINING BUSINESS CONFIDENTIAL INFORMATION]
EX2659	Mylan Pharmaceuticals Inc. and Novo Nordisk Settlement Agreement [UNDER SEAL AS CONTAINING BUSINESS CONFIDENTIAL INFORMATION]

Respectfully submitted by:

/*Megan Raymond/*
Megan Raymond (Reg. No. 72,997)
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
801 17th Street NW, Suite 1050
Washington, DC 20006
P: (202) 505-5878
megan.raymond@groombridgewu.com

J. Steven Baughman (Reg. No. 47,414)
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
801 17th Street NW, Suite 1050
Washington, DC 20006
P: (202) 505-5832
steve.baughman@groombridgewu.com

Jenny C. Wu (*pro hac vice*)
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
565 5th Avenue, Suite 2900
New York, NY 10017
P: (332) 269-0038
jenny.wu@groombridgewu.com

Michael Milea (Reg. No. 71,863)
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
565 5th Avenue, Suite 2900
New York, NY 10017
P: (332) 269-0029
mike.milea@groombridgewu.com

Philip S. May (*pro hac vice*)
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP

801 17th Street NW, Suite 1050
Washington, DC 20006
P: (202) 539-6620
philip.may@groombridgewu.com

Joshua Reich (Reg. No. 75,338)
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
565 5th Avenue, Suite 2900
New York, NY 10017
P: (332) 269-0024
joshua.reich@groombridgewu.com

Attorneys For Patent Owner Novo Nordisk A/S

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of PATENT OWNER'S EXHIBIT LIST has been served in its entirety by causing the aforementioned document to be electronically mailed to the following attorneys of record for Mylan, Dr. Reddy's, Sun, and Apotex listed below. Exhibits 2657-2659 have only been served on Mylan's counsel of record.

Petitioners' Counsel of Record:

Lead Counsel:	Brandon M. White Reg. No. 52,354 White-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 By Electronic Mail
Backup Counsel:	Emily J. Greb Reg. No. 68,244 Greb-ptab@perkinscoie.com Perkins Coie LLP 33 East Main Street Madison, WI 53703 Telephone: (608) 663-7460 Courtney Prochnow, PhD Reg. No. 67,639 Prochnow-ptab@perkinscoie.com Perkins Coie LLP 633 W. 5th St., Ste 5850 Los Angeles, CA 90071 Telephone: (310) 788-9900

	Christopher D. Jones Reg. No. 76,472 Jones-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 Jonathan I. Tietz, PhD Reg. No. 76,753 Tietz-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 Matthew A. Lembo Reg. No. 75,633 Lembo-ptab@perkinscoie.com Perkins Coie LLP 1155 Avenue of the Americas Floor 22 New York, NY 10036 Telephone: (212) 262-6900 Shannon M. Bloodworth SBloodworth@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 David L. Anstaett DAnstaett@perkinscoie.com Perkins Coie LLP 33 East Main Street Madison, WI 53703

	Telephone: (608) 663-7460 Bryan D. Beel BBeel@perkinscoie.com Perkins Coie LLP 1120 NW Couch St. Portland, OR 97209 Telephone: (503) 727-2000 Nathan Kelley Kelley_nathan-ptab@perkinscoie.com Perkins Coie LLP 700 13th Street, NW Washington, DC 20005 Telephone: (202) 654-6200 Rodney Swartz Reg. No. 73,343 RSwartz@perkinscoie.com Perkins Coie LLP 1120 NW Couch St. 10th Floor Portland, OR 97209 Telephone: (503) 727-2000 Jessica Kaiser Reg No. 58,937 kaiser-ptab@perkinscoie.com Perkins Coie LLP 1900 Sixteenth St., Suite 1400 Denver, CO 80202-5255 Tel: (303) 291-2300 Semaglutide-Ozempic@perkinscoie.com By Electronic Mail
Lead Counsel for Dr. Reddy's Laboratories,	Jovial Wong Reg. No. 60,115 Winston & Strawn LLP

Inc. and Dr. Reddy's Laboratories. Ltd.:	1901 L Street NW Washington, DC 20036 Telephone: (202) 282-5867 jwong@winston.com By Electronic Mail
Backup Counsel:	Scott Border Reg. No. 77,744 Winston & Strawn LLP 1901 L Street NW Washington, DC 20036 Telephone: (202) 285-5054 sborder@winston.com Sharon Lin McIntosh (*pro hac vice* to be submitted) Winston & Strawn LLP 1901 L Street NW Washington, DC 20036 Telephone: (202) 285-5756 slin@winston.com By Electronic Mail

Lead Counsel for Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.:	Brian Sodikoff Katten Munchin Rosenman LLP 525 West Monroe Street Chicago, IL 60661 P: (312) 902-5200 brian.sodikoff@katten.com By Electronic Mail

Backup Counsel:	Christopher B. Ferenc Katten Munchin Rosenman LLP 1919 Pennsylvania Ave., N.W. Suite 800 Washington, DC 20006 P: (202) 625-3500 christopher.ferenc@katten.com By Electronic Mail

Lead Counsel for Apotex Inc.:	John J. Molenda Steptoe LLP 1114 Avenue of the Americas New York, NY P: (212-506-3900) jmolenda@steptoe.com By Electronic Mail

Backup Counsel:	Lawerence Kass Steptoe LLP 1114 Avenue of the Americas New York, NY P: (212-506-3900) lkass@steptoe.com Tyler Doh Steptoe LLP 1114 Avenue of the Americas New York, NY P: (212-506-3900) tdoh@steptoe.com Michael I. Green Steptoe LLP 1114 Avenue of the Americas New York, NY P: (212-506-3900) migreen@steptoe.com Semaglutide@Steptoe.com By Electronic Mail

Dated: October 4, 2024

Respectfully Submitted,

By: /*Sayem Osman*/
Sayem Osman